Thomas B Kristensen

List of Publications by Year
in descending order

39 papers	1,524 citations	535685 17 h-index	355658 38 g-index
39 all docs	39 docs citations	39 times ranked	1548 citing authors

#	Article	IF	Citations
1	IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load. Haematologica, 2022, 107, 877-886.	1.7	5
2	Genomic profiling of a randomized trial of interferon-Î± vs hydroxyurea in MPN reveals mutation-specific responses. Blood Advances, 2022, 6, 2107-2119.	2.5	26
3	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1953-1963.	2.0	20
4	Validation of dermatopathological criteria to diagnose cutaneous lesions of mastocytosis: importance of <scp>KIT D816V</scp> mutation analysis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1367-1375.	1.3	7
5	Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis. American Journal of Human Genetics, 2021, 108, 284-294.	2.6	12
6	Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis. International Journal of Molecular Sciences, 2021, 22, 2562.	1.8	9
7	Fatal anaphylaxis following a hornet sting in a yellow jacket venom-sensitized patient with undetected monoclonal mast cell activation syndrome and without previous history of a systemic sting reaction. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 401-403.e2.	2.0	10
8	Clinical validation of a new commercial highly sensitive KIT D816V mutation analysis in mastocytosis. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1489-1491.	2.7	5
9	Towards rational diagnostics in mastocytosis: clinical validation of sensitive KIT D816V mutation analysis of unfractionated whole-blood. Leukemia and Lymphoma, 2019, 60, 268-270.	0.6	4
10	International external quality assurance of JAK2 V617F quantification. Annals of Hematology, 2019, 98, 1111-1118.	0.8	3
11	Venom anaphylaxis can mimic other serious conditions and disclose important underlying disease. Annals of Allergy, Asthma and Immunology, 2018, 120, 338-339.	0.5	1
12	Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 230-238.	2.7	88
13	Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment. Epigenomics, 2018, 10, 1155-1166.	1.0	7
14	Prospective evaluation of the diagnostic value of sensitive <scp>KIT</scp> D816V mutation analysis of blood in adults with suspected systemic mastocytosis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1737-1743.	2.7	32
15	Patterns of anaphylaxis after diagnostic workup: A followâ€up study of 226 patients with suspected anaphylaxis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1944-1952.	2.7	38
16	Comparison of <scp>gDNA</scp>â€based versus <scp>mRNA</scp>â€based <scp>KIT</scp> D816V mutation analysis reveals large differences between blood andÂbone marrow in systemic mastocytosis. British Journal of Haematology, 2017, 178, 330-332.	1.2	6
17	Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. Acta Dermato-Venereologica, 2016, 96, 602-612.	0.6	21
18	<scp>LPL</scp> gene expression is associated with poor prognosis in <scp>CLL</scp> and closely related to <scp>NOTCH</scp>1 mutations. European Journal of Haematology, 2016, 97, 175-182.	1.1	13

#	Article	IF	Citations
19	Targeted ultradeep nextâ€generation sequencing as a method for <scp>KIT</scp><scp>D</scp>816<scp>V</scp> mutation analysis in mastocytosis. European Journal of Haematology, 2016, 96, 381-388.	1.1	10
20	Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain, 2016, 139, 1348-1360.	3.7	93
21	Recognizing mastocytosis in patients with anaphylaxis: Value of KIT D816V mutation analysis of peripheral blood. Journal of Allergy and Clinical Immunology, 2015, 135, 262-264.	1.5	47
22	KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia, 2015, 29, 1223-1232.	3.3	229
23	High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia. Leukemia Research, 2015, 39, 555-560.	0.4	17
24	Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1267-1274.	2.7	139
25	Epidemiology of systemic mastocytosis in Denmark. British Journal of Haematology, 2014, 166, 521-528.	1.2	154
26	Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. American Journal of Hematology, 2014, 89, 493-498.	2.0	96
27	Clinical Relevance of Sensitive and Quantitative STAT3 Mutation Analysis Using Next-Generation Sequencing in T-Cell Large Granular Lymphocytic Leukemia. Journal of Molecular Diagnostics, 2014, 16, 382-392.	1.2	18
28	Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet, The, 2013, 382, 1380.	6.3	35
29	KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2013, 132, 723-728.	1.5	40
30	Low Incidence of Minor BRAF V600 Mutation-Positive Subclones in Primary and Metastatic Melanoma Determined by Sensitive and Quantitative Real-Time PCR. Journal of Molecular Diagnostics, 2013, 15, 355-361.	1.2	8
31	Serum tryptase correlates with the <scp>KIT</scp> D816V mutation burden in adults with indolent systemic mastocytosis. European Journal of Haematology, 2013, 91, 106-111.	1.1	51
32	<i>KIT</i> D816V Mutation-Positive Cell Fractions in Lesional Skin Biopsies from Adults with Systemic Mastocytosis. Dermatology, 2013, 226, 233-237.	0.9	10
33	Systemic mastocytosis is uncommon inKITD816V mutation positive core-binding factor acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 1338-1344.	0.6	9
34	Circulating <scp>KIT</scp><scp>D</scp>816<scp>V</scp> mutationâ€positive nonâ€mast cells in peripheral blood are characteristic of indolent systemic mastocytosis. European Journal of Haematology, 2012, 89, 42-46.	1.1	44
35	Improved Detection of the KIT D816V Mutation in Patients with Systemic Mastocytosis Using a Quantitative and Highly Sensitive Real-Time qPCR Assay. Journal of Molecular Diagnostics, 2011, 13, 180-188.	1.2	157
36	Vacuum Sealing and Cooling as Methods to Preserve Surgical Specimens. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 460-469.	0.6	14

#	Article	IF	Citations
37	NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression*. European Journal of Haematology, 2011, 87, 400-408.	1.1	36
38	Mutation in the Nucleophosmin Gene (NPM1) Is a Stable Marker for Minimal Residual Disease Monitoring in Acute Myeloid Leukemia Patients with Increased Sensitivity and Specificity Compared to Expression of the Wilms Tumor (WT1) Gene.. Blood, 2009, 114, 1602-1602.	0.6	0
39	Serum zinc in homosexual men with antibodies against human immunodeficiency virus.. Clinical Chemistry, 1988, 34, 1929-1930.	1.5	10